Table of Contents

company-logo

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Virpax Pharmaceuticals Dividend Announcement

• Virpax Pharmaceuticals does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Virpax Pharmaceuticals dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Virpax Pharmaceuticals Dividend History

Virpax Pharmaceuticals Dividend Yield

Virpax Pharmaceuticals current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Virpax Pharmaceuticals stock? Use our calculator to estimate your expected dividend yield:

Virpax Pharmaceuticals Financial Ratios

P/E ratio-0.08
PEG ratio0.00
P/B ratio-0.47
ROE-1554.74%
Payout ratio0.00%
Current ratio0.48
Quick ratio0.48
Cash Ratio0.35

Virpax Pharmaceuticals Dividend FAQ

Does Virpax Pharmaceuticals stock pay dividends?
Virpax Pharmaceuticals does not currently pay dividends to its shareholders.
Has Virpax Pharmaceuticals ever paid a dividend?
No, Virpax Pharmaceuticals has no a history of paying dividends to its shareholders. Virpax Pharmaceuticals is not known for its dividend payments.
Why doesn't Virpax Pharmaceuticals pay dividends?
There are several potential reasons why Virpax Pharmaceuticals would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Virpax Pharmaceuticals ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Virpax Pharmaceuticals has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Virpax Pharmaceuticals a dividend aristocrat?
Virpax Pharmaceuticals is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Virpax Pharmaceuticals a dividend king?
Virpax Pharmaceuticals is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Virpax Pharmaceuticals a dividend stock?
No, Virpax Pharmaceuticals is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Virpax Pharmaceuticals stocks?
To buy Virpax Pharmaceuticals you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Virpax Pharmaceuticals stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.